From the Departments of Neurosurgery (D.W., J.R.M., D.A.N., C.P.K., J.T.F., J.D.M., R.A.D.L.).
Neurology (J.T.F.).
AJNR Am J Neuroradiol. 2017 Oct;38(10):1978-1983. doi: 10.3174/ajnr.A5309. Epub 2017 Jul 27.
Thrombectomy trials are often specifically interpreted as evidence for the effectiveness of stent retrievers. The effectiveness of other thrombectomy techniques such as aspiration thrombectomy should be validated through further investigation and review.
To evaluate published treatment times and clinical outcomes in patients treated with aspiration thrombectomy or ADAPT (A Direct Aspiration, First Pass Technique) for acute ischemic stroke.
A systematic literature review was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE, Scopus, and the Cochrane trial register were searched on November 8, 2016.
Twenty studies ( = 1523 patients) were included in this review and meta-analysis. One of these studies was prospective, and the rest were retrospective.
Meta-analysis was performed by using a random effects model. Data and publication bias were visualized with forest plots and funnel plots.
Five studies investigated aspiration thrombectomy only, and 16 studies investigated ADAPT. Of the 16 studies on ADAPT, the rate of successful recanalization (TICI 2b/3) was 89.3% (95% CI, 85.4%-92.3%). The proportion of patients with good clinical outcome (90-day mRS ≤2) was 52.7% (95% CI, 48.0%-57.4%).
Studies on ADAPT were retrospective, and there was heterogeneity between studies for successful recanalization ( < .001) and good clinical outcome ( < .001). There was evidence of publication bias for recanalization rates ( = .01), but not for clinical outcomes ( = .42).
ADAPT and aspiration thrombectomy are effective approaches to thrombectomy, with high recanalization rates and excellent clinical outcomes reported in the literature. Aspiration thrombectomy is a promising neurointervention, but large prospective randomized studies are needed to validate its utility.
取栓试验通常被专门解读为支架取栓器有效性的证据。其他取栓技术,如抽吸血栓切除术的有效性应通过进一步的研究和综述加以验证。
评估采用抽吸血栓切除术或 ADAPT(直接抽吸,初次通过技术)治疗急性缺血性脑卒中患者的已发表的治疗时间和临床结局。
按照系统评价和荟萃分析的首选报告项目(PRISMA)指南进行系统文献回顾。于 2016 年 11 月 8 日检索 MEDLINE、Scopus 和 Cochrane 试验注册库。
纳入本综述和荟萃分析的 20 项研究(=1523 例患者)。其中 1 项为前瞻性研究,其余为回顾性研究。
采用随机效应模型进行荟萃分析。使用森林图和漏斗图可视化数据和发表偏倚。
5 项研究仅调查了抽吸血栓切除术,16 项研究调查了 ADAPT。在 16 项 ADAPT 研究中,再通率(TICI 2b/3)为 89.3%(95%可信区间,85.4%-92.3%)。90 天 mRS 评分≤2 的患者比例为 52.7%(95%可信区间,48.0%-57.4%)。
ADAPT 的研究为回顾性,再通率(<0.001)和良好临床结局(<0.001)方面的研究存在异质性。再通率存在发表偏倚的证据(=0.01),但临床结局没有(=0.42)。
ADAPT 和抽吸血栓切除术是有效的取栓方法,文献报道其再通率高,临床结局良好。抽吸血栓切除术是一种很有前途的神经介入治疗方法,但需要进行大型前瞻性随机研究来验证其效用。